Bacterial Pneumonia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 55 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bacterial Pneumonia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bacterial Pneumonia - Pipeline Review, H2 2014', provides an overview of the Bacterial Pneumonia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Pneumonia Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Pneumonia - Overview 7
Pipeline Products for Bacterial Pneumonia - Comparative Analysis 8
Bacterial Pneumonia - Therapeutics under Development by Companies 9
Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes 10
Bacterial Pneumonia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bacterial Pneumonia - Products under Development by Companies 14
Bacterial Pneumonia - Products under Investigation by Universities/Institutes 15
Bacterial Pneumonia - Companies Involved in Therapeutics Development 16
Paratek Pharmaceuticals, Inc. 16
Bayer AG 17
ImmuVen, Inc. 18
Humabs BioMed SA 19
Dong-A Socio Group 20
Bacterial Pneumonia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
amikacin sulfate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tedizolid phosphate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
omadacycline tosylate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
IMV-0123 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MAb Against S. aureus - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine Targeting Lipoprotein for Pneumococcal Infection - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bacterial Pneumonia - Recent Pipeline Updates 40
Bacterial Pneumonia - Dormant Projects 48
Bacterial Pneumonia - Product Development Milestones 49
Featured News & Press Releases 49
Oct 25, 2013: Synflorix receives positive opinion from the CHMP in Europe for additional pneumonia indication 49
Apr 16, 2013: Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution In Mechanically Ventilated Patients With Gram-negative Pneumonia 49
Oct 16, 2012: Cubist Pharma To Feature Clinical Data On CXA-201 At Inaugural IDWeek Annual Meeting 50
Oct 08, 2012: Cempra Announces Phase I Study Results Of Intravenous Solithromycin 50
Sep 05, 2012: Rib-X Pharma To Present Data On Antibiotic Candidate Radezolid At ICAAC 2012 51
Apr 13, 2012: Cempra To Present Overview On Solithromycin At Future Leaders In Biotechnology Industry Conference 51
Apr 02, 2012: Tetraphase Presents Data On TP-834 At 22nd European Congress Of Clinical Microbiology And Infectious Disease 51
Apr 02, 2012: Dong Wha Pharma Announces Initiation Of Phase III Trial Of Its Antibacterial Agent DW224a 52
Mar 31, 2012: Cempra Presents Phase II Clinical Trial Data Of CEM-101 In Community-Acquired Bacterial Pneumonia Patients At ECCMID 52
Mar 29, 2012: Cempra To Present Clinical Data Of CEM-101 At Needham Health Care Conference 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Number of Products under Development for Bacterial Pneumonia, H2 2014 7
Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Bacterial Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 16
Bacterial Pneumonia - Pipeline by Bayer AG, H2 2014 17
Bacterial Pneumonia - Pipeline by ImmuVen, Inc., H2 2014 18
Bacterial Pneumonia - Pipeline by Humabs BioMed SA, H2 2014 19
Bacterial Pneumonia - Pipeline by Dong-A Socio Group, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Bacterial Pneumonia Therapeutics - Recent Pipeline Updates, H2 2014 40
Bacterial Pneumonia - Dormant Projects, H2 2014 48